AOXG OTC
Aoxing Pharmaceutical Company, Inc.
1W: +0.0%
1M: +4.8%
3M: -46.3%
YTD: -62.7%
1Y: -68.6%
3Y: +120.0%
5Y: -85.0%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±60.0%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$33K
+0.0% ▲
5Y CAGR: -69.5%
Gross Profit
$33K
+0.0% ▲
5Y CAGR: -64.4%
Operating Income
-$23K
-217.0% ▼
Net Income
-$23K
-142.3% ▼
EPS (Diluted)
$0.00
-100.0% ▼
EBITDA
-$23K
-141.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2014 | FY2015 | FY2023 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $25M | $32M | $0 | $0 | $33K |
| YoY Growth | +100.0% | +26.9% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $6M | $8M | $0 | $0 | $214 |
| Gross Profit | $20M | $25M | $0 | $0 | $33K |
| Gross Margin | 77.7% | 75.9% | — | — | 99.4% |
| R&D Expenses | $337K | $3M | $0 | $0 | $0 |
| SG&A Expenses | $10M | $15M | $15K | $7K | $56K |
| Operating Expenses | $11M | $18M | $15K | $7K | $56K |
| Operating Income | $9M | $6M | -$15K | -$7K | -$23K |
| Operating Margin | 34.1% | 19.3% | — | — | -69.1% |
| Interest Expense | $6M | $3M | $0 | $0 | $241 |
| Income Before Tax | $3M | $3M | -$15K | $55K | -$23K |
| Tax Expense | -$3M | $642K | $0 | $0 | $0 |
| Net Income | $5M | $2M | -$15K | $55K | -$23K |
| Net Margin | 21.6% | 6.4% | — | — | -69.8% |
| EPS (Diluted) | $0.09 | $0.03 | $-0.00 | $0.00 | $0.00 |
| EBITDA | $9M | $7M | -$15K | $55K | -$23K |
| Shares Outstanding | 63M | 75M | 341M | 381M | 381M |